Recombinant protein vaccines formulated with enantiospecific cationic lipid R-DOTAP and methods of use thereof

By combining R-DOTAP with recombinant influenza antigens, the vaccine composition formed solves the problem of insufficient immunogenicity of recombinant protein vaccines, achieves strong CD8 T cell and antibody responses, and provides effective immune protection against influenza viruses.

CN120641124APending Publication Date: 2025-09-12PDS BIOTECH CORP
2 Cites 0 Cited by

Patent Information

Application Number
CN202380077249.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-09-18
Filing Date
2023-10-23
Publication Date
2025-09-12

AI Technical Summary

Technical Problem

Existing recombinant protein vaccines generally lack immunogenicity, resulting in weak immune responses, and different adjuvants have inconsistent effects on different diseases, making it difficult to effectively induce strong CD8 T cell responses and neutralizing antibody responses against respiratory viruses.

Method used

The enantiospecific cationic lipid R-DOTAP is combined with recombinant influenza antigens to form a vaccine composition. The recombinant protein is delivered to the MHC class I and class II processing pathways through cationic lipid nanoparticles, activating the necessary immune response pathways and enhancing CD8 T cell and antibody responses.

Benefits of technology

It significantly enhanced the immunogenicity of the influenza recombinant protein vaccine, induced strong CD8+ effector T cell, CD4+ effector T cell and memory T cell responses, produced broadly neutralizing antibodies, and provided effective immune protection against influenza virus.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are vaccine compositions comprising recombinant protein antigens derived from computationally optimized broad reactive influenza antigen (COBRA) proteins and immunomodulators and methods of using the same. In some embodiments, the vaccine composition comprises one or more COBRA proteins, and the immunomodulator is a cationic lipid. The cationic lipid is prepared from R-DOTAP (4, 4 ', 4' '- Methods of use of the vaccine composition include a method of inducing a humoral immune response against influenza virus in a subject, a method of inducing multifunctional CD8 + and CD4 + effector T cells against influenza virus, a method of inducing memory T cells against influenza virus, and a method of inducing multi-functional CD8 + and CD4 + effector T cells against influenza virus. Methods of enhancing immunity against influenza viruses and methods of inducing a balanced Th1 / Th2 immune response against influenza viruses.
Need to check novelty before this filing date? Find Prior Art